| Jiyong Lee, | |
|
5530 Wisconsin Ave Ste 700, Chevy Chase, MD 20815-4401 | |
| (301) 656-5050 | |
| (301) 654-4237 |
| Full Name | Jiyong Lee |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 9 Years |
| Location | 5530 Wisconsin Ave Ste 700, Chevy Chase, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235516014 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD046103 (District Of Columbia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sibley Memorial Hospital | Washington, DC | Hospital |
| Suburban Hospital | Bethesda, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cardiocare Llc | 1254332729 | 14 |
News Archive
Researchers at Leiden University have made a breakthrough in the study of the hereditary Pompe disease. Together with colleagues in York, they have developed a molecule that binds to the enzyme that is key to the progress of the disease. The findings have been published in ACS Central Science.
Researchers have identified the cells that likely give rise to the brain tumor subtype Group 4 medulloblastoma. The finding removes a barrier to developing more effective targeted therapies against the brain tumor's most common subtype.
Despite the routine delivery of babies by caesarean section, there is no consensus among medical practitioners on which is the best operating method to use.
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
› Verified 5 days ago
| Entity Name | Cardiocare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235293937 PECOS PAC ID: 1254332729 Enrollment ID: O20070125000447 |
News Archive
Researchers at Leiden University have made a breakthrough in the study of the hereditary Pompe disease. Together with colleagues in York, they have developed a molecule that binds to the enzyme that is key to the progress of the disease. The findings have been published in ACS Central Science.
Researchers have identified the cells that likely give rise to the brain tumor subtype Group 4 medulloblastoma. The finding removes a barrier to developing more effective targeted therapies against the brain tumor's most common subtype.
Despite the routine delivery of babies by caesarean section, there is no consensus among medical practitioners on which is the best operating method to use.
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jiyong Lee, 5530 Wisconsin Ave Ste 700, Chevy Chase, MD 20815-4401 Ph: (301) 656-5050 | Jiyong Lee, 5530 Wisconsin Ave Ste 700, Chevy Chase, MD 20815-4401 Ph: (301) 656-5050 |
News Archive
Researchers at Leiden University have made a breakthrough in the study of the hereditary Pompe disease. Together with colleagues in York, they have developed a molecule that binds to the enzyme that is key to the progress of the disease. The findings have been published in ACS Central Science.
Researchers have identified the cells that likely give rise to the brain tumor subtype Group 4 medulloblastoma. The finding removes a barrier to developing more effective targeted therapies against the brain tumor's most common subtype.
Despite the routine delivery of babies by caesarean section, there is no consensus among medical practitioners on which is the best operating method to use.
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
› Verified 5 days ago
Dr. Rachel Kaiser, MD, MPH Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5454 Wisconsin Ave, Suite 600, Chevy Chase, MD 20815 Phone: 301-942-7600 | |
Dr. Allen A. Nimetz, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5530 Wisconsin Ave, Suite 700, Chevy Chase, MD 20815 Phone: 301-656-5050 Fax: 301-654-4237 | |
Dr. Ankit B Shah, M.D., M.P.H. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 8401 Connecticut Ave Ste 104, Chevy Chase, MD 20815 Phone: 240-892-7070 Fax: 240-248-0606 | |
Dr. Steve A Burka, MD Cardiovascular Disease Medicare: May Accept Medicare Assignments Practice Location: 5530 Wisconsin Ave, #914, Chevy Chase, MD 20815 Phone: 301-654-3803 Fax: 301-654-3808 | |
Dr. Mark A Miller, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 4411 Leland St, Chevy Chase, MD 20815 Phone: 301-496-0815 | |
Dr. Sara Goldkind, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5630 Wisconsin Ave Apt 807, Chevy Chase, MD 20815 Phone: 240-353-0866 | |
Dr. Robert J Marshall, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5530 Wisconsin Ave Ste 700, Chevy Chase, MD 20815 Phone: 301-656-5050 Fax: 301-654-4237 |